Achillion Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of Hematology Detailing Novel Results With Factor D Inhibitors
05 nov. 2015 09h03 HE
|
Achillion Pharmaceuticals, Inc.
- Highly potent, specific, and oral factor D inhibitors effectively block hemolysis of paroxysmal nocturnal hemoglobinuria (PNH) cells and mitigate the accumulation of C3 fragments – -...
Achillion to Present at the Credit Suisse 24th Annual Healthcare Conference
02 nov. 2015 06h05 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Nov. 02, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
Achillion Reports Second Quarter and Six Month 2015 Financial Results
10 août 2015 06h05 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and six months ended June 30, 2015. For the second...
$1.5 million gift to The Jackson Laboratory establishes Sims Family Fund for SMARD Research
05 août 2015 16h08 HE
|
The Jackson Laboratory
BAR HARBOR, Maine, Aug. 5, 2015 (GLOBE NEWSWIRE) -- A $1.5 million gift to The Jackson Laboratory (JAX) from Mr. Grant Sims and Ms. Patricia (Patty) Sims of Houston, Texas, will fund research in a...
Aegerion Pharmaceuticals Announces Participation at Wells Fargo Securities 2012 Healthcare Conference
13 juin 2012 08h00 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 13, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
Aegerion Pharmaceuticals Announces Webcast of Investor Presentations at Upcoming Conferences
09 févr. 2012 08h00 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 9, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
Aegerion Pharmaceuticals Announces Lomitapide 78-Week Phase III Clinical Data Consistent With Earlier Results
06 janv. 2012 12h57 HE
|
Aegerion Pharmaceuticals, Inc.
Efficacy and Safety Profile Maintained
Company to Webcast Presentation at the 30th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 6, 2012 (GLOBE NEWSWIRE) -- Aegerion...
Sandford D. Smith Appointed to Aegerion Pharmaceuticals' Board of Directors
20 déc. 2011 08h00 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Dec. 20, 2011 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...